Oncologist
Dr. Trinanjan Basu
Dr. Trinanjan Basu is a reputed Medical Oncologist in Mumbai with more than 20 years of experience in this field.
Dr. Trinanjan Basu
Dr. Trinanjan Basu completed his MBBS from R.G. Kar Medical College, Kolkata, followed by an MD in Radiation Oncology from the West Bengal University of Health Sciences. He further enhanced his expertise by earning a CAS-Pr (Switzerland) certification and has received advanced training in CyberKnife–Advanced Robotic Radiation Therapy. His academic background and specialized training have provided a strong foundation in radiation oncology, advanced radiotherapy techniques, and evidence-based cancer care.
Dr. Trinanjan Basu is a Senior Consultant and Head of the Department of Radiation Oncology at HCG Cancer Hospital, Borivali, Mumbai. With over 15 years of experience, he has treated more than 5,000 cancer patients and has expertise in IMRT, VMAT, SRS, SBRT, PET-CT-based treatment planning, and CyberKnife-based radiation therapy. Before joining HCG, he served as a Senior Registrar at Tata Memorial Hospital, Mumbai, Clinical Associate at Kokilaben Dhirubhai Ambani Hospital, and Associate Consultant at Medanta – The Medicity, Gurgaon. He has authored more than 35 national and international peer-reviewed publications, received several prestigious international grants and awards, and actively contributes to oncology research and professional societies.
- Benign and malignant brain tumors
- Head and neck cancers with IMRT/VMAT
- Application of SRS/SBRT in brain
- Spine
- Lung and Prostate Malignancies
- [Commentary] SBRT (Stereotactic Body Radiotherapy) in Recurrent Head Neck Cancer – Boon or Bane?
- Multi-Institutional Clinical Outcomes of Biopsy Gleason Grade Group 5 Prostate Cancers Treated With Contemporary High-Dose Radiation and Long-Term Androgen Deprivation Therapy
- Towards a comprehensive head‑and‑neck oncological radiology (HNOR) consortium: Are we there yet?
- Safety, Efficacy and Quality of Life with Stereotactic Radiotherapy (SBRT) in High Risk, Node Positive and Oligometastatic Prostate Cancers
- Multi-Institutional Clinical Outcomes of Biopsy Gleason Grade Group 5 Prostate Cancers Treated With Contemporary High-Dose Radiation and Long-Term Androgen Deprivation Therapy
- Simultaneous integrated boost (SIB) stereotactic body radiotherapy (SBRT) for prostate and pelvic nodes in high risk, node positive and oligometastatic prostate cancers: Safety, efficacy and quality of life outcome measures.
- Stereotactic Body Radiotherapy and Immunotherapy for Older Patients with Oligometastases: A Proposed Paradigm by the International Geriatric Radiotherapy Group